. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Infect Dis Clin North Am. 2022 Mar;36(1):125–146. doi: 10.1016/j.idc.2021.11.004

Table 3.

CMV reactivation risk and prophylaxis regimens in transplant

Serostatus	Organ	Risk of CMV Reactivation	Recommendation
D−/R−	All Organs	Low	Prophylaxis not recommended
D+/R−	HCT	Intermediate	100 d
	Kidney, liver, or heart	High	3–6 mo^a
	Lung	High	6–12 mo
D−/R+	HCT	High	100 d
	Kidney, liver, or heart	Intermediate	3–6 mo
	Lung	High	6–12 mo^b
D+/R+	HCT	High	100 d
	Kidney, liver, or heart	Intermediate	3–6 mo
	Lung	High	6–12 mo^b

Abbreviations: D+, donor seropositive; D−, donor seronegative; HCT, hematopoietic stem cell transplantation; R+, recipient seropositive; R−, recipient seronegative

Valganciclovir is not approved for use as prophylaxis in liver transplantation²⁹

CMV immune globulin is sometimes given to high-risk lung transplant recipients, in addition to antiviral prophylaxis⁴